Paul Horton, Vishal Patel, C L Hall, Karen C Johnston, Yajun Mei, Ofer Sadan
{"title":"探讨葡萄糖矫正治疗与患者长期预后之间的相关性:一项SHINE二级分析。","authors":"Paul Horton, Vishal Patel, C L Hall, Karen C Johnston, Yajun Mei, Ofer Sadan","doi":"10.3389/fneur.2025.1567766","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Glucose control is an important aspect of acute ischemic stroke management. Although absolute glucose concentration remains the focus in clinical stroke care, glucose variability is increasingly recognized as a viable treatment target. To assess the relationship between acute post-stroke glycemic control parameters and patient outcomes, we reanalyzed the data from the first 8 h of treatment for patients in the Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial, when glycemic variability is highest.</p><p><strong>Methods: </strong>In this secondary analysis of the SHINE dataset, the rate of glucose change during the first 8 h was evaluated for its association with patient outcomes, dichotomized as modified Rankin scale (mRS) 0-2 versus 3-6, using logistic regression and a linear mixed-effects model.</p><p><strong>Results: </strong>Unadjusted analysis of the glucose correction period during the first 8 h suggested that patients with mRS 3-6 had a faster glucose correction compared to those with mRS 0-2 (-8.9 and -6.7 mg/dL/h, <i>p</i> < 0.001). This finding remained statistically significant in both the intensive intervention group and the poorly controlled diabetic sub-group (glycosylated hemoglobin [HbA1c] ≥ 6.4). Mixed-effects models also indicated a significant difference in the rate of glucose change (1.9 mg/dL/h, <i>p</i> < 0.001) between outcome groups (mRS 0-2 versus 3-6) across both treatment and HbA1c sub-groups.</p><p><strong>Conclusion: </strong>Analysis of the first 8 h of the SHINE data suggests that early, rapid correction of glucose is associated with poor outcomes, particularly in the sub-group of patients with HbA1c ≥ 6.4. Further research is warranted to assess early glycemic correction as a possible personalized glucose management goal.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"16 ","pages":"1567766"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119312/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the correlation between corrective glucose treatment and long-term patient outcomes: a SHINE secondary analysis.\",\"authors\":\"Paul Horton, Vishal Patel, C L Hall, Karen C Johnston, Yajun Mei, Ofer Sadan\",\"doi\":\"10.3389/fneur.2025.1567766\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Glucose control is an important aspect of acute ischemic stroke management. Although absolute glucose concentration remains the focus in clinical stroke care, glucose variability is increasingly recognized as a viable treatment target. To assess the relationship between acute post-stroke glycemic control parameters and patient outcomes, we reanalyzed the data from the first 8 h of treatment for patients in the Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial, when glycemic variability is highest.</p><p><strong>Methods: </strong>In this secondary analysis of the SHINE dataset, the rate of glucose change during the first 8 h was evaluated for its association with patient outcomes, dichotomized as modified Rankin scale (mRS) 0-2 versus 3-6, using logistic regression and a linear mixed-effects model.</p><p><strong>Results: </strong>Unadjusted analysis of the glucose correction period during the first 8 h suggested that patients with mRS 3-6 had a faster glucose correction compared to those with mRS 0-2 (-8.9 and -6.7 mg/dL/h, <i>p</i> < 0.001). This finding remained statistically significant in both the intensive intervention group and the poorly controlled diabetic sub-group (glycosylated hemoglobin [HbA1c] ≥ 6.4). Mixed-effects models also indicated a significant difference in the rate of glucose change (1.9 mg/dL/h, <i>p</i> < 0.001) between outcome groups (mRS 0-2 versus 3-6) across both treatment and HbA1c sub-groups.</p><p><strong>Conclusion: </strong>Analysis of the first 8 h of the SHINE data suggests that early, rapid correction of glucose is associated with poor outcomes, particularly in the sub-group of patients with HbA1c ≥ 6.4. Further research is warranted to assess early glycemic correction as a possible personalized glucose management goal.</p>\",\"PeriodicalId\":12575,\"journal\":{\"name\":\"Frontiers in Neurology\",\"volume\":\"16 \",\"pages\":\"1567766\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119312/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fneur.2025.1567766\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fneur.2025.1567766","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
血糖控制是急性缺血性脑卒中治疗的一个重要方面。虽然绝对葡萄糖浓度仍然是临床卒中护理的重点,但葡萄糖变异性越来越被认为是一个可行的治疗目标。为了评估急性卒中后血糖控制参数与患者预后之间的关系,我们重新分析了卒中高血糖胰岛素网络努力(SHINE)临床试验中患者治疗的前8 h的数据,此时血糖变异性最高。方法:在SHINE数据集的二次分析中,使用逻辑回归和线性混合效应模型,评估前8 h内葡萄糖变化率与患者结局的相关性,并将其分为修改的Rankin量表(mRS) 0-2和3-6。结果:对前8 h血糖校正期的未经校正分析表明,mRS 3-6的患者比mRS 0-2的患者(-8.9和-6.7 mg/dL/h, p p )血糖校正更快。结论:对SHINE前8 h数据的分析表明,早期、快速的血糖校正与不良预后相关,特别是在HbA1c ≥ 6.4的患者亚组中。需要进一步的研究来评估早期血糖矫正作为个性化血糖管理目标的可能性。
Exploring the correlation between corrective glucose treatment and long-term patient outcomes: a SHINE secondary analysis.
Introduction: Glucose control is an important aspect of acute ischemic stroke management. Although absolute glucose concentration remains the focus in clinical stroke care, glucose variability is increasingly recognized as a viable treatment target. To assess the relationship between acute post-stroke glycemic control parameters and patient outcomes, we reanalyzed the data from the first 8 h of treatment for patients in the Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial, when glycemic variability is highest.
Methods: In this secondary analysis of the SHINE dataset, the rate of glucose change during the first 8 h was evaluated for its association with patient outcomes, dichotomized as modified Rankin scale (mRS) 0-2 versus 3-6, using logistic regression and a linear mixed-effects model.
Results: Unadjusted analysis of the glucose correction period during the first 8 h suggested that patients with mRS 3-6 had a faster glucose correction compared to those with mRS 0-2 (-8.9 and -6.7 mg/dL/h, p < 0.001). This finding remained statistically significant in both the intensive intervention group and the poorly controlled diabetic sub-group (glycosylated hemoglobin [HbA1c] ≥ 6.4). Mixed-effects models also indicated a significant difference in the rate of glucose change (1.9 mg/dL/h, p < 0.001) between outcome groups (mRS 0-2 versus 3-6) across both treatment and HbA1c sub-groups.
Conclusion: Analysis of the first 8 h of the SHINE data suggests that early, rapid correction of glucose is associated with poor outcomes, particularly in the sub-group of patients with HbA1c ≥ 6.4. Further research is warranted to assess early glycemic correction as a possible personalized glucose management goal.
期刊介绍:
The section Stroke aims to quickly and accurately publish important experimental, translational and clinical studies, and reviews that contribute to the knowledge of stroke, its causes, manifestations, diagnosis, and management.